Silo Pharma Inc Stock Price, News & Analysis

Silo Pharma (Nasdaq: SILO) has announced a strategic expansion into cryptocurrency treasury management, focusing on Bitcoin, Ethereum, and Solana. The company has appointed crypto infrastructure expert Corwin Yu as the first member of its new Crypto Advisory Board to spearhead this initiative.

The strategy includes opportunistic digital currency purchases and yield generation through staking, supported by newly acquired AI-powered market intelligence technology. Simultaneously, Silo Pharma continues its biopharmaceutical focus, with its PTSD drug SPC-15 approaching FDA IND application submission.

Silo Pharma (Nasdaq: SILO) has completed dosing in a FDA-requested 7-day safety and toxicology large animal study for its lead PTSD drug candidate SPC-15. The bioanalytical and safety/toxicology results are expected within 60 days.

The company is progressing with two remaining preclinical studies: an IND-enabling GLP-compliant toxicology study and a device study for SPC-15's microchip-based nasal spray system. Silo plans to pursue the FDA's 505(b)(2) regulatory pathway for SPC-15's approval, which could potentially accelerate clinical timelines and reduce development costs.

Silo Pharma (Nasdaq: SILO) announced significant progress in the development of SPC-15, its novel intranasal PTSD drug candidate. The company expects to receive crucial preclinical study data within 30-90 days, including results from GLP-compliant toxicology studies and an FDA-requested safety study.

The company plans to submit an IND application by end of 2025, potentially leading to Phase 1 clinical trials in 2026. Silo intends to pursue the FDA's 505(b)(2) regulatory pathway to expedite development. Notably, SPC-15's unique approach targets stress resilience, differentiating it from existing PTSD treatments, in a market where no new drugs have been approved in nearly 25 years.

Silo Pharma (NASDAQ:SILO) has entered into a non-binding letter of intent with Hoth Therapeutics (NASDAQ:HOTH) to form a 50:50 joint venture targeting the $16 billion global obesity market. The collaboration focuses on developing a novel therapeutic platform based on glial cell line-derived neurotrophic factor (GDNF), exclusively licensed from the U.S. Department of Veterans Affairs and co-developed with Emory University.

The technology, protected under U.S. Patent No. 10,052,362, targets multiple conditions including obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. The partnership combines Hoth's regulatory expertise with Silo's translational capabilities to address a significant unmet need, as obesity affects over 40% of U.S. adults, with veterans being particularly impacted.

Hoth Therapeutics (NASDAQ: HOTH) and Silo Pharma (NASDAQ: SILO) have formed a 50/50 joint venture to develop and commercialize a novel obesity treatment licensed from the U.S. Department of Veterans Affairs. The therapy is based on Glial Cell Line-Derived Neurotrophic Factor (GDNF), targeting obesity and non-alcoholic fatty liver disease (NAFLD).

The technology, protected under U.S. Patent No. 10,052,362, aims to address a $100B+ market with potential applications for type 2 diabetes and central obesity. The partnership combines the VA's clinical infrastructure, Hoth's regulatory expertise, and Silo's translational capabilities to develop this first-in-class treatment targeting the neuroinflammatory root of obesity.

Silo Pharma (NASDAQ: SILO) has received a Notice of Allowance from the USPTO for a patent application related to biomarkers for PTSD therapeutic treatments. The patent (Application No. 17/954,858), licensed from Columbia University, will be issued as U.S. Patent No. 12,329,726 on June 17, 2025. This strengthens IP protection for Silo's lead asset SPC-15, an intranasal PTSD treatment approaching Phase 1 clinical trials. The original patent was developed by Columbia University with NIH grant support. Through an exclusive global license agreement with Columbia University, Silo holds rights to develop, manufacture, and commercialize SPC-15.

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, announced its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The strategic decision aims to diversify the company's treasury holdings with a digital store of value. CEO Eric Weisblum stated that the Bitcoin investment is intended to serve as an inflation hedge and is expected to help preserve and optimize long-term shareholder value. The company, which focuses on novel therapeutics and drug delivery systems, is making this move as part of its treasury management strategy.

Silo Pharma (NASDAQ: SILO) has partnered with medical technology provider Resyca BV for a drug-device study of SPC-15, its lead asset for post-traumatic stress disorder (PTSD) treatment. The study will focus on the formulation-specific microchip-based nasal spray system used to deliver the drug.

The intranasal delivery system is designed to bypass the blood-brain barrier, potentially enabling faster therapeutic benefits with optimized safety. This study is expected to provide the final device data and documentation needed for the company's planned FDA IND submission in 2025.

Additionally, Silo is conducting two other SPC-15 studies: an IND-enabling GLP-compliant toxicology and toxicokinetics study, and an FDA-requested 7-day safety and toxicology large animal study.

Silo Pharma (NASDAQ: SILO) has successfully closed a $2 million public offering of 3,333,338 shares of common stock at $0.60 per share, along with Series A-1 and A-2 warrants. The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $0.60 per share. H.C. Wainwright & Co. served as the exclusive placement agent. The developmental stage biopharmaceutical company plans to use the net proceeds for general working capital purposes.